Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Status:
Recruiting
Trial end date:
2021-12-02
Target enrollment:
Participant gender:
Summary
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic
adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding
to the GLP-1 receptor (GLP-1R),thus,it has physiological effects such as glucose-dependent
insulin synthesis and secretion, inhibition of β-cell apoptosis, promotion of β-cell
proliferation and regeneration, inhibition of glucagon secretion, reduction of food intake,
delay of gastric emptying, enhancement of glucose utilization in peripheral tissues and
reduction of glycogen output. Liraglutide injection,developed and marketed as Victoza® by
Novo Nordisk,is indicated for the treatment of patients with type 2 diabetes and was approved
by the U.S. Food and Drug Administration in 2010.This 26-week trial compares the effectivity
on glycaemic control,safety and immunogenicity of liraglutide injection and Victoza® in
patients with type 2 diabetes inadequately controlled by oral metformin alone.